colorful burb

Analysis

Life sciences and health care M&A update: Q4 2023

Continued demand and focus in life sciences on speed to market, sustainable strategies, safer installations, and competition for qualified labor are driving alternative approaches to project delivery and design.

Life sciences and health care trends

  • Health care services
    With patients resuming more normal patterns of care following the pandemic, hospitals are witnessing positive margin stabilization.1
  • Health care technology
    Despite a decrease in EBITDA performance, sentiment surrounding health care technology has resulted in rising enterprise values through Q4 2023.2
  • Life sciences and pharma services
    Continued demand and focus in Life Sciences on speed to market, sustainable strategies, safer installations, and competition for qualified labor are driving alternative approaches to project delivery and design.3
  • Medical devices and supplies
    Overall trends in the medical device sector point toward optimism, propelled by a continued rise in digital therapeutics and at-home diagnostics, growing use of biometric devices, and increased speed to market.4
  • Payors and payor services
    Payors and Payor services faced challenges in 2023, including ongoing Medicaid redeterminations and increased Medicare usage, but stability is anticipated in 2024.5

This newsletter is a periodic compilation of certain capital markets information. Information contained in this newsletter should not be construed as a recommendation to sell or a recommendation to buy any security. Any reference to or omission of any reference to any company in this newsletter shall not be construed as a recommendation to sell, buy, or take any other action with respect to any security of any such company. We are not soliciting any action with respect to any security or company based on this newsletter. This newsletter is published solely for the general information of clients and friends of Deloitte Corporate Finance LLC. It does not take into account the particular investment objectives, financial situation, or needs of individual recipients. Certain transactions, including those involving early-stage companies, give rise to substantial risk and are not suitable for all investors. This newsletter is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. Prediction of future events is inherently subject to both known risks, uncertainties, and other factors that may cause actual results to vary materially. We are under no obligation to update the information contained in this newsletter. We and our affiliates and related entities, partners, principals, directors, and employees, including persons involved in the preparation or issuance of this newsletter, may from time to time have “long” and “short” positions in, and buy or sell, the securities, or derivatives (including options) thereof, of companies mentioned herein. The companies mentioned in this newsletter may be: (i) investment banking clients of Deloitte Corporate Finance LLC; or (ii) clients of Deloitte Financial Advisory Services LLP and its related entities. The decision to include any company for mention or discussion in this newsletter is wholly unrelated to any audit or other services that Deloitte Corporate Finance LLC may provide or to any audit services or any services that any of its affiliates or related entities may provide to such company. No part of this newsletter may be copied or duplicated in any form by any means, or redistributed without the prior written consent of Deloitte Corporate Finance LLC.

Fullwidth SCC. Do not delete! This box/component contains JavaScript that is needed on this page. This message will not be visible when page is activated.

Did you find this useful?